US20140113294A1 - Direct nucleic acid amplification kit, reagent and method - Google Patents
Direct nucleic acid amplification kit, reagent and method Download PDFInfo
- Publication number
- US20140113294A1 US20140113294A1 US13/799,800 US201313799800A US2014113294A1 US 20140113294 A1 US20140113294 A1 US 20140113294A1 US 201313799800 A US201313799800 A US 201313799800A US 2014113294 A1 US2014113294 A1 US 2014113294A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- cyclodextrin
- dried reagent
- reagent composition
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 80
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 78
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 78
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 63
- 238000012197 amplification kit Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 86
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 48
- 230000003321 amplification Effects 0.000 claims abstract description 46
- 229920000858 Cyclodextrin Polymers 0.000 claims description 30
- 239000000872 buffer Substances 0.000 claims description 26
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 25
- 238000003752 polymerase chain reaction Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 14
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 14
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 229920001917 Ficoll Polymers 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 11
- 229940098773 bovine serum albumin Drugs 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 230000009089 cytolysis Effects 0.000 claims description 6
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 239000003352 sequestering agent Substances 0.000 claims description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 3
- PCWPQSDFNIFUPO-VDQKLNDWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-37,39,41,43,45,47,49-heptakis(2-hydroxyethoxy)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38,40,42,44,46,48-heptol Chemical compound OCCO[C@H]1[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]1O[C@@H]2CO)[C@@H](O)[C@@H]8OCCO)[C@@H](O)[C@@H]7OCCO)[C@@H](O)[C@@H]6OCCO)[C@@H](O)[C@@H]5OCCO)[C@@H](O)[C@@H]4OCCO)[C@@H](O)[C@@H]3OCCO PCWPQSDFNIFUPO-VDQKLNDWSA-N 0.000 claims description 2
- QFSFPJHBIGWPMD-PBVGKYIBSA-N 104723-60-6 Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](OC[C@@H]2[C@H]3O[C@@H]4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)O[C@@H]4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)O[C@@H]4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)OC4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)O[C@@H]4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)O[C@@H]4[C@H](O)[C@@H](O)[C@@H]([C@H](O4)CO)O[C@H]([C@@H]([C@H]3O)O)O2)[C@H](O)[C@H]1O QFSFPJHBIGWPMD-PBVGKYIBSA-N 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 238000011901 isothermal amplification Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000012545 processing Methods 0.000 abstract description 6
- 238000011109 contamination Methods 0.000 abstract description 5
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000004108 freeze drying Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010006785 Taq Polymerase Proteins 0.000 description 10
- 239000011521 glass Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 238000007496 glass forming Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000012807 PCR reagent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- -1 RE960 Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000620137 Carboxydothermus hydrogenoformans Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000718543 Ormosia krugii Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/125—Specific component of sample, medium or buffer
Definitions
- the present invention relates to the field of nucleic acid amplification, particularly to the use of a polymerase chain reaction to amplify nucleic acids.
- the invention provides methods and kits which can be used to amplify nucleic acids by lyophilizing or freeze-drying nucleic acid amplification reagents for easy amplification of nucleic acid samples.
- the invention has applications in the easy processing of nucleic acids and is particularly useful in genotyping, diagnostics and forensics.
- PCR polymerase chain reaction
- U.S. Pat. No. 5,705,345 (Lundin et al.) describes a method of nucleic acid preparation whereby the sample containing cells is lysed to release nucleic acid and the sample is treated with cyclodextrin to neutralize the extractant.
- the advantage of this system is that conventional detergent removal requires a separation step; however the addition of cyclodextrin to neutralize the detergent removes the need for the separation step and thus reduces the risk of contamination.
- WO 99/38962 (Health, Gentra Systems Inc.) describes a solid support with a bound lysis reagent.
- the lysis reagent can comprise a detergent, a chelating agent, water and optionally an RNA digesting enzyme.
- the method for PCR amplification requires further steps for purification of the nucleic acid for amplification analysis.
- WO 91/02040 describes an invention using cyclodextrin-labelled primers in an amplification reaction mixture for qualitative and quantitative nucleic acid sequence analysis.
- the benefits of this invention are a higher signal efficiency and versatility in label colours.
- WO 95/32739 (Agrawal) describes an oligonucleotide non-covalently complexed with a cyclodextrin.
- cyclodextrin with oligonucleotides was for the cellular uptake of oligonucleotides and not for the amplification of nucleotides in a PCR reaction.
- WO 2010/066908 (Beckers et al.,) describes the use of cyclodextrins to improve the specificity, sensitivity and/or yield of PCR.
- the method discloses an amplification reaction which is performed in a reaction mixture comprising at least one cyclodextrin and performing the amplification reaction on the reaction mixture. Again the advantage being a combination of cyclodextrin in the liquid amplification reaction mixture would reduce the risk of contamination by reducing the number of purification steps.
- column-based nucleic acid purification is a typical solid phase extraction method to purify nucleic acids. This method relies on the nucleic acid binding through adsorption to silica or other supports depending on the pH and the salt content of the buffer.
- suitable buffers include Tris-EDTA (TE) buffer or Phosphate buffer (used in DNA microarray experiments due to the reactive amines).
- TE Tris-EDTA
- Phosphate buffer used in DNA microarray experiments due to the reactive amines.
- Nucleic acid purification on spin columns typically involves three time-consuming and complex steps/stages: the sample containing nucleic acid is added to the column and the nucleic acid binds due to the lower pH (relative to the silanol groups on the column) and salt concentration of the binding solution, which may contain buffer, a denaturing agent (such as guanidine hydrochloride), Triton X-100, isopropanol and a pH indicator; the column is washed with 5 mM KPO 4 pH 8.0 or similar, 80% EtOH); and the column is eluted with buffer or water.
- a denaturing agent such as guanidine hydrochloride
- Triton X-100 Triton X-100
- isopropanol a pH indicator
- the column is washed with 5 mM KPO 4 pH 8.0 or similar, 80% EtOH
- the column is eluted with buffer or water.
- chaotropic agents such that DNA binds to silica or glass particles or glass beads. This property was used to purify nucleic acid using glass powder or silica beads under alkaline conditions.
- Typical chaotropic agents include guanidinium thiocyanate or guanidinium hydrochloride and recently glass beads have been substituted with glass containing minicolumns.
- the best defense against PCR amplification failure in forensics applications is to combine sound sample handling and processing techniques with extraction systems proven to efficiently purify DNA.
- PCR reagents are stored in glycerol solution which must be maintained at temperatures below room temperature.
- Lyophilisation or freeze drying is a process widely used in the preparation of reagents for nucleic acid analysis and other biological processes because it allows for long term stability of otherwise labile biomolecules, and provides a convenient method of storage, shipping and reconstitution.
- Current technology for producing dry biological reagent compositions involves procedures such as dry-blending, spray-drying, freeze-drying, fluidized bed drying, and/or cryogenic freezing. All of these procedures have limitations and drawbacks including consistency and reliability.
- Spray-drying technology provides more homogeneous blends of chemicals because the reagents are first dissolved in solution. With spray-drying, however, it is difficult to dispense precise amounts of blended chemicals. To overcome this drawback, the resulting particles are usually reprocessed by agglomeration to obtain uniform particle sizes such as tablets. However, the agglomerated particles are generally less soluble than the original spray-dried particles or powders. Also, these procedures sometimes use fluorocarbon cryogenic solutions which can be hazardous to the environment.
- Fluid bed technology (Rubina, 1999 , Pharmaceutical Technology, 23, 104-113) relies upon spraying a liquid reagent blend onto a particle and drying the liquid to obtain a particle coated with the blended reagents. Using this procedure, it is difficult to obtain uniformly sized particles and to produce a uniform coating.
- freeze-drying Another method for stabilizing biologics is freeze-drying.
- One drawback to the freeze-drying is the use of fluorocarbon refrigerants which are difficult to dispose of and the freeze-drying process may be imprecise and also difficult to regulate. Indeed, regular freeze drying of reagents may not provide an entire solution for particularly labile reagents used in molecular biology processes. Furthermore, degradation of the product during the freeze drying process is common and a freeze dried product is not always perfectly stable during storage. Process control is critical and can be difficult to regulate (Tang & Pakil, 2004, Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice; Pharmaceutical Research, 21, 191-200).
- Another method of stabilizing biologics is by air-drying biological reagent compositions (Ratti, 2001, Hot Air and Freeze-Drying of High Value Foods: A Review. J. Food Engineering 49, 311-319).
- Some problems with air drying processes are that the dried product is not in a readily dispensable form.
- the biological reagents must be stable at or above the temperature of the drying process and it is a difficult process to control accurately.
- One type of carrier or filler which has been used to stabilize biological reagents are glass-forming filler materials (U.S. Pat. No. 5,565,318).
- the biological reagent solutions are incorporated into the glass-forming filler materials (which are water soluble or a water-swellable substance). They are then dried to produce a glassy composition which immobilizes and stabilizes the biological reagent (U.S. Pat. No. 5,593,824).
- Carbohydrates such as glucose, sucrose, maltose or maltotriose are an important group of glass-forming substances.
- Other polyhydroxy compounds can be used such as carbohydrate derivatives like sorbitol and chemically modified carbohydrates.
- Another important class of glass-forming substances are synthetic polymers such as polyvinyl pyrrolidone, polyacrylamide, or polyethyleneimine.
- glass-forming substances include sugar copolymers such as FicollTM (U.S. Pat. No. 3,300,474).
- Ficoll is a neutral, highly branched, high-mass, hydrophilic polysaccharide which dissolves readily in aqueous solutions. Ficoll radii range from 2-7 nm. It is prepared by reaction of the polysaccharide with epichlorohydrin.
- Ficoll has molecular weights of between 5,000 to 1,000,000 and contains sucrose residues linked through ether bridges to bifunctional groups. Such groups may be an alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms. The bifunctional groups serve to connect sugar residues together.
- These polymers may, for example, be made by the reaction of sugar with a halohydrin or bis-epoxy compound.
- a glass is typically defined as an undercooled liquid with a very high viscosity,
- the present invention provides methods and kits which can be used to amplify nucleic acids by incorporating all the required PCR reagents into a lyophilized format for easy amplification of nucleic acid samples.
- a dried reagent composition for nucleic acid amplification comprising, a sequestering reagent, a polymerase and a deoxyribonucleotide triphosphate (dNTP).
- dNTP deoxyribonucleotide triphosphate
- the nucleic acid is selected from the group consisting of DNA, RNA and oligonucleotide.
- nucleic acid is used herein synonymously with the term “nucleotides” and includes DNA, such as plasmid DNA and genomic DNA; RNA, such as mRNA, tRNA, sRNA and RNAi; and protein nucleic acid, PNA.
- the sequestering agent is a cyclodextrin.
- the cyclodextrin may be selected from a group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and derivatives thereof. Cyclodextrin could consist of a group consisting of 6-O- ⁇ -D-Maltosyl- ⁇ cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin and 2-hydroxypropyl- ⁇ -cyclodextrin.
- the sequestrant is preferably ⁇ -cyclodextrin.
- the sequestering reagent is not a chelating agent.
- a chelating agent is a chemical compound that combines with a metal to form a chelate, often used to trap heavy metal ions (Colins English Dictionary, ⁇ HarperCollins Publishers 2003).
- a lysis reagent is sodium dodecyl suphate; sodium is a metal ion however according to Ramamurthy Palepu and Vincent C. Reinsborough (Can J. Chem Vol 66, 325-328, 1988) it is the hydrophobic tail that interacts with the cyclodextrin not the hydrophilic head.
- the dried reagent composition comprises at least one primer.
- the dried reagent composition additionally comprises an excipient mix.
- excipient mix is used herein to denote additives or ingredients used to make up a preparation or mixture and for example may comprise of PCR buffer, Ficoll 70, Ficoll 400, Melezitose, Trehalose, stabilising proteins and nuclease free water.
- PCR buffer is used herein to denote a buffer necessary to create optimal conditions for activity of a DNA polymerase and for example may comprise of Tris-HCl, KCl, MgCl 2 , gelatin and nuclease free water.
- the dried reagent composition additionally comprises an exchange buffer.
- exchange buffer is used herein to denote a buffer used for the removal of small ionic solutes, whereby one buffer is removed and replaced with another alternative buffer and for example may comprise of Tris/HCl, CaCl 2 , a detergent, RE960, MgCl 2 , KCl and nuclease free water.
- the dried reagent composition additionally comprises bovine serum albumin (BSA).
- BSA bovine serum albumin
- the polymerase is an OmniKlen Taq (OKT) Polymerase.
- the polymerase may be selected from the group consisting of T4 DNA Polymerase, Pol I and Klenow Fragment, T4 DNA Polymerase, Modified Bacteriophage T7 DNA Polymerase, Terminal Deoxynucleotide Transferase, Bst Polymerase, Taq Polymerase, Tth polymerase, Pow Polymerase, Vent Polymerase, Pab Pol I DNA Polymerase, Thermus thermophiles, Carboxydothermus hydrogenoformans, SP6 and SP7 RNA polymerase.
- the preferred embodiment is a dried reagent composition
- ⁇ -cyclodextrin comprising ⁇ -cyclodextrin, at least one primer, a polymerase, dNTP, BSA, an excipient mix and an exchange buffer.
- a method for producing a dried reagent composition for nucleic acid amplification comprising the steps:
- the mixture additionally comprises at least one primer.
- the mixture additionally comprises an excipient mix.
- the mixture additionally comprises an exchange buffer.
- the drying step is achieved by lyophilizing the mixture.
- amplification of nucleic acid comprising the steps:
- the amplification method is a polymerase chain reaction.
- the amplification method comprises reverse transcription polymerase chain reaction or isothermal amplification.
- the solution is formed by adding water to the nucleic acid.
- the nucleic acid is immobilized on a solid support.
- the solid support is a cellulose based matrix.
- the solid matrix is selected from the group consisting of glass, glass fiber, glass microfiber, silica, silica gel, silica oxide, cellulose, nitrocellulose, carboxymethylcellulose, polyester, polyamide, carbohydrate polymers, polypropylene, polytetraflurorethylene, polyvinylidinefluoride, wool and porous ceramics.
- the solid matrix may comprise a glass or silica-based solid phase medium, a plastics-based solid phase medium or a cellulose-based solid phase medium.
- the solid support is preferably a cellulose-based matrix. Examples of cellulose-based matrices include FTATM (data file 51668), 903 neonatal cards and 31-ETF cards available from GE Healthcare.
- the cellulose based matrix is in the form of a pre punched disc.
- the cellulose based matrix is in the form of an FTA pre punched disc.
- the lysis reagent is embedded onto said solid matrix.
- the lysis reagent comprises an anionic surfactant or detergent.
- Sodium dodecyl sulphate (SDS) is an example of an anionic surfactant frequently used to lyse biological cells.
- the amplification is carried out in a single reaction vessel such as a test tube or the well of a multi-well plate.
- the method of the invention can be used either in a single reaction well or a high-throughput 96-well format in combination with automated sample processing as described by Baron et al., (2011, Forensics Science International: Genetics Supplement Series, 93, e560-e561).
- This approach would involve a minimal number of steps and increase sample throughput.
- the risk of operator-induced error, such as cross-contamination is also reduced since this procedure requires fewer manipulations compared to protocols associated with currently used, more labor intensive kits (e.g. QIAmp DNA blood mini kit, Qiagen).
- the risk of sample mix-up is also reduced since the procedure requires few manipulations.
- the method is readily transferable to a multi-well format for high-throughput screening.
- the present invention can thus improve sample processing for carrying out PCR reactions to aid genetic interrogations.
- the invention can be conducted in a 96 well/high throughput format to facilitate sample handling and thus eliminate batch processing of samples.
- the advantage of dried or lyophilized formulations of the polymerase chain reaction reagents is that they can be easily solubilized by the addition of water, thus saving operator time and facilitating operator usage.
- the dried reagent mixture can be pre-dispensed into the reaction vessel, such as the well of a multi-well plate.
- the preformulated, predispensed, ambient-temperature-stable beads or cakes allow amplification reactions to be carried out within a single well or reaction vessel and ensure greater reproducibility between reactions, minimize pipetting steps, and reduce the potential for pipetting errors and contamination.
- a detection system comprising the steps:
- the detection system is a PCR imaging system.
- the detection system is a fluorescence or luminescent based system.
- nucleic acid may be viral, prokaryotic or eukaryotic in origin.
- the nucleic acid sample is present in a cellular sample.
- the cellular sample may originate from a mammal, bird, fish or plant or a cell culture thereof.
- the cellular sample is mammalian in origin, most preferably human in origin.
- the sample containing the nucleic acid may be derived from any source. This includes, for example, physiological/pathological body fluids (e.g.
- the method is for use as a tool selected from the group consisting of a molecular diagnostics tool, a human identification tool, a forensics tool, STR profiling tool and DNA profiling.
- a kit for amplifying nucleic acid comprising the dried reagent composition hereinbefore described and instructions for use thereof.
- FIG. 1 shows the results from PCR amplification of unwashed blood-spotted FTA paper with nucleic acid amplification reagent cakes with or without ⁇ -cyclodextrin.
- FIG. 2 shows the results from PCR amplification of unwashed blood-spotted FTA paper with nucleic acid amplification reagent cakes with ⁇ -cyclodextrin.
- FIG. 3 shows results from PCR amplification of titrated OmniKlen Taq (OKT) polymerase, in nucleic acid amplification reagent cakes, demonstrating the best concentration to freeze dry the nucleic acid amplification formulation.
- OKT OmniKlen Taq
- FTA papers for storing nucleic acid were obtained from GE Healthcare UK Limited; Normal human blood (Tissue Solutions Ltd); Genomic DNA (Promega product code G152A); 1 kb DNA ladder (Promega product code G571A); Harris Uni-core punch, 1.2 mm (Sigma, Catalogue number Z708860-25ea, lot 3110); OmniKlentaq Polymerase (Mo Bio Inc, catalogue code 1225-250); Deoxyribonucleotide triphosphate (dNTP) (Life Tech);
- Samples were combined with the lyophilised nucleic acid amplification composition in a 96 well plate.
- Blood-spotted FTA was added to a well with a nucleic acid amplification reagent cake that contained cyclodextrin or did not contain cyclodextrin.
- Standards and samples were added to the appropriate wells.
- the plates were centrifuged at 1000 rpm for 1 minute and sealed. PCR was carried out on an MJ Research PTC-200 Thermo Cycler following the manufacturer's user instructions.
- the thermal cycling conditions were: 95° C. for 5 min, 95° C. for 30 sec, 55/65° C. for 1 min, 72° C. for 2 min followed by 35 cycles of: 95° C. for 30 sec, 55/65° C. for 1 min, 72° C. 2 min, followed by 72° C. for 10 mins.
- the standard well of the 96 well PCR plate was loaded with 5 ⁇ l of the 1 Kb DNA ladder with 1 ⁇ l of 6 ⁇ loading buffer.
- FIG. 1 shows PCR amplification of unwashed blood-spotted FTA with the lyophilized nucleic acid amplification composition with or without ⁇ -cyclodextrin: Lane M: 1 kb Ladder; Lane 1-4: FTA punch spotted with whole blood (1.2 mm) with a lyophilized nucleic acid amplification composition without cyclodextrin; Lane 5-8: FTA punch spotted with whole blood (1.2 mm) with the lyophilized nucleic acid amplification composition containing cyclodextrin.
- FIG. 2 shows PCR amplification of unwashed blood-spotted FTA with the lyophilized nucleic acid amplification composition with or without ⁇ -cyclodextrin: Lane M: 1 kb Ladder; Lane 1-2: FTA punch spotted with whole blood (1.2 mm) with the lyophilized nucleic acid amplification composition containing cyclodextrin; Lane 3-4: FTA punch (1.2 mm) with the lyophilized nucleic acid amplification composition containing cyclodextrin; Lane 5-6: FTA punch spotted with whole blood (1.2 mm) with the lyophilized nucleic acid amplification composition without cyclodextrin.
- FIG. 3 shows PCR amplification of unwashed blood-spotted FTA with the lyophilized nucleic acid amplification composition without ⁇ -cyclodextrin and with varying concentrations of OKT Taq polymerase: Lane 1-8 contains 6U OKT, Lane 1-3 FTA punch spotted with whole blood, Lane 4-6 genomic DNA, Lane 7-8 no DNA template; Lane 9-16 contains 8U OKT, Lane 9-11 FTA punch spotted with whole blood, Lane 12-14 genomic DNA, Lane 15-16 no DNA template; Lane 17-24 contains 10U OKT, Lane 17-19 FTA punch spotted with whole blood, Lane 20-22 genomic DNA, Lane 23-24 no DNA template; Lane 25-32 contains 12U OKT, Lane 25-27 FTA punch spotted with whole blood, Lane 28-30 genomic DNA, Lane 31-32 no DNA template.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015538433A JP2015533507A (ja) | 2012-10-24 | 2013-10-23 | 直接核酸増幅キット、試薬及び方法 |
PCT/EP2013/072206 WO2014064169A1 (en) | 2012-10-24 | 2013-10-23 | Direct nucleic acid amplification kit, reagent and method |
IN2793DEN2015 IN2015DN02793A (enrdf_load_stackoverflow) | 2012-10-24 | 2013-10-23 | |
EP13779893.0A EP2912191B1 (en) | 2012-10-24 | 2013-10-23 | Direct nucleic acid amplification kit, reagent and method |
CN202110196732.2A CN112899354A (zh) | 2012-10-24 | 2013-10-23 | 直接核酸扩增试剂盒、试剂和方法 |
CN201380055445.3A CN104736726A (zh) | 2012-10-24 | 2013-10-23 | 直接核酸扩增试剂盒、试剂和方法 |
US15/432,476 US10907201B2 (en) | 2012-10-24 | 2017-02-14 | Direct nucleic acid amplification kit, reagent and method |
JP2018128740A JP7009011B2 (ja) | 2012-10-24 | 2018-07-06 | 直接核酸増幅キット、試薬及び方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1219137.5 | 2012-10-24 | ||
GB201219137A GB201219137D0 (en) | 2012-10-24 | 2012-10-24 | Direct nucleic acid amplification kit, reagent and method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/432,476 Division US10907201B2 (en) | 2012-10-24 | 2017-02-14 | Direct nucleic acid amplification kit, reagent and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140113294A1 true US20140113294A1 (en) | 2014-04-24 |
Family
ID=47359421
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/799,800 Abandoned US20140113294A1 (en) | 2012-10-24 | 2013-03-13 | Direct nucleic acid amplification kit, reagent and method |
US15/432,476 Active 2034-03-07 US10907201B2 (en) | 2012-10-24 | 2017-02-14 | Direct nucleic acid amplification kit, reagent and method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/432,476 Active 2034-03-07 US10907201B2 (en) | 2012-10-24 | 2017-02-14 | Direct nucleic acid amplification kit, reagent and method |
Country Status (7)
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140322761A1 (en) * | 2013-03-29 | 2014-10-30 | Sony Corporation | Method of preparing sample for nucleic acid amplification reaction, nucleic acid amplification method, and reagent and microchip for solid phase nucleic acid amplification reaction |
WO2016099999A1 (en) * | 2014-12-18 | 2016-06-23 | Ge Healthcare Uk Limited | Analyte detection on a solid support by nucleic acid amplification coupled to an immunoassay |
WO2016106113A1 (en) * | 2014-12-23 | 2016-06-30 | Ge Healthcare Uk Limited | Methods and reagents for reverse-transcription polymerase chain reaction |
WO2016106129A3 (en) * | 2014-12-23 | 2016-12-08 | Ge Healthcare Uk Limited | Methods and reagents for reverse-transcription polymerase chain reaction |
WO2017036808A1 (en) * | 2015-08-28 | 2017-03-09 | Ge Healthcare Uk Limited | A method and kit for analyte detection |
US10590408B2 (en) | 2016-02-18 | 2020-03-17 | Ge Healthcare Uk Limited | Method and composition for biomolecule stabilization |
US10907201B2 (en) | 2012-10-24 | 2021-02-02 | Global Life Sciences Solutions Operations UK Ltd | Direct nucleic acid amplification kit, reagent and method |
US10968478B2 (en) | 2014-12-23 | 2021-04-06 | Global Life Sciences Solutions Operations UK Ltd | Methods and reagents for reverse-transcription polymerase chain reaction |
US11286526B2 (en) * | 2017-05-19 | 2022-03-29 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
CN114317700A (zh) * | 2021-12-28 | 2022-04-12 | 无锡科智达科技有限公司 | 荧光pcr试剂冻干保护剂、冻干方法及应用 |
EP4289507A3 (en) * | 2017-07-10 | 2024-02-28 | Gen-Probe Incorporated | Analytical systems and methods for nucleic acid amplification using sample assigning parameters |
US11987836B2 (en) | 2014-09-30 | 2024-05-21 | Global Life Sciences Solutions Usa Llc | Method for nucleic acid analysis directly from an unpurified biological sample |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3378948B1 (en) * | 2015-11-18 | 2020-11-04 | Japan Agency for Marine-Earth Science and Technology | Method for quantifying target nucleic acid and kit therefor |
US9617587B1 (en) | 2016-04-04 | 2017-04-11 | Nat Diagnostics, Inc. | Isothermal amplification components and processes |
CN106755414B (zh) * | 2016-12-23 | 2020-09-01 | 宁波海尔施基因科技有限公司 | 一种检测dna遗传标记的方法 |
EP4119664A4 (en) * | 2020-03-11 | 2024-04-24 | Kao Corporation | Method for preparing rna derived from skin surface lipids |
CN111593112A (zh) * | 2020-05-12 | 2020-08-28 | 深圳市星蝶科技有限公司 | 一种用于检测β-地中海贫血的PCR试剂及试剂盒 |
CA3212208A1 (en) * | 2021-03-19 | 2022-09-22 | Honghua Zhang | Isothermal amplification of pathogens |
WO2025049920A1 (en) * | 2023-09-01 | 2025-03-06 | Biomeme, Inc. | Methods and compositions for sample processing |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705345A (en) * | 1991-01-10 | 1998-01-06 | Amersham International Plc | Methods and kits for preparing nucleic acids using cyclodextrin |
US5972386A (en) * | 1995-12-19 | 1999-10-26 | Flinders Technologies Pty, Ltd. | Dry solid medium for storage and analysis of genetic material |
US20060160078A1 (en) * | 2002-07-12 | 2006-07-20 | Cardy Donald L N | Lateral flow assay device and method |
US7462475B2 (en) * | 2004-05-20 | 2008-12-09 | Dna Poleymerase Technology, Inc. | Use of whole blood in PCR reactions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565318A (en) * | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
US7122304B2 (en) * | 1997-05-12 | 2006-10-17 | Whatman, Inc. | Methods for the storage and synthesis of nucleic acids using a solid support |
AU2574499A (en) * | 1998-02-02 | 1999-08-16 | Gentra Systems, Inc. | Compositions and methods for using a lysing matrix for isolating dna |
CN101516337A (zh) * | 2006-09-18 | 2009-08-26 | 通用电气医疗集团生物科学公司 | 用玻璃覆盖的生物学试剂的制备 |
EP2063866B2 (en) * | 2006-09-18 | 2017-08-23 | GE Healthcare Bio-Sciences Corp. | Preparation of glassified biological reagents |
US8153401B2 (en) | 2007-05-17 | 2012-04-10 | Applied Biosystems, Llc | Method for direct amplification from crude nucleic acid samples |
SI2294225T1 (sl) * | 2008-06-30 | 2015-04-30 | Life Technologies Corporation | Postopek za neposredno amplifikacijo iz vzorcev surove nukleinske kisline |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
CN102018672B (zh) * | 2010-11-29 | 2013-09-18 | 广州朗圣药业有限公司 | 一种水溶性药物的脂质体冻干组合物及其制备方法 |
GB201219137D0 (en) | 2012-10-24 | 2012-12-05 | Ge Healthcare Uk Ltd | Direct nucleic acid amplification kit, reagent and method |
FR2998845B1 (fr) * | 2012-12-04 | 2016-04-01 | Autoliv Dev | Generateur de gaz |
-
2012
- 2012-10-24 GB GB201219137A patent/GB201219137D0/en not_active Ceased
-
2013
- 2013-03-13 US US13/799,800 patent/US20140113294A1/en not_active Abandoned
- 2013-10-23 CN CN201380055445.3A patent/CN104736726A/zh active Pending
- 2013-10-23 IN IN2793DEN2015 patent/IN2015DN02793A/en unknown
- 2013-10-23 EP EP13779893.0A patent/EP2912191B1/en active Active
- 2013-10-23 WO PCT/EP2013/072206 patent/WO2014064169A1/en active Application Filing
- 2013-10-23 JP JP2015538433A patent/JP2015533507A/ja active Pending
- 2013-10-23 CN CN202110196732.2A patent/CN112899354A/zh active Pending
-
2017
- 2017-02-14 US US15/432,476 patent/US10907201B2/en active Active
-
2018
- 2018-07-06 JP JP2018128740A patent/JP7009011B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705345A (en) * | 1991-01-10 | 1998-01-06 | Amersham International Plc | Methods and kits for preparing nucleic acids using cyclodextrin |
US5972386A (en) * | 1995-12-19 | 1999-10-26 | Flinders Technologies Pty, Ltd. | Dry solid medium for storage and analysis of genetic material |
US20060160078A1 (en) * | 2002-07-12 | 2006-07-20 | Cardy Donald L N | Lateral flow assay device and method |
US7462475B2 (en) * | 2004-05-20 | 2008-12-09 | Dna Poleymerase Technology, Inc. | Use of whole blood in PCR reactions |
Non-Patent Citations (1)
Title |
---|
Kermekchiev et al. (2009) Nucl. Acids res. Vol. 37 no 5 e40 doi.1093/nar/gkn1055 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10907201B2 (en) | 2012-10-24 | 2021-02-02 | Global Life Sciences Solutions Operations UK Ltd | Direct nucleic acid amplification kit, reagent and method |
US20140322761A1 (en) * | 2013-03-29 | 2014-10-30 | Sony Corporation | Method of preparing sample for nucleic acid amplification reaction, nucleic acid amplification method, and reagent and microchip for solid phase nucleic acid amplification reaction |
US11987836B2 (en) | 2014-09-30 | 2024-05-21 | Global Life Sciences Solutions Usa Llc | Method for nucleic acid analysis directly from an unpurified biological sample |
WO2016099999A1 (en) * | 2014-12-18 | 2016-06-23 | Ge Healthcare Uk Limited | Analyte detection on a solid support by nucleic acid amplification coupled to an immunoassay |
US11008604B2 (en) | 2014-12-18 | 2021-05-18 | Global Life Sciences Solutions Operations UK Ltd | Analyte detection on a solid support by nucleic acid amplification coupled to an immunoassay |
CN107208136A (zh) * | 2014-12-18 | 2017-09-26 | 通用电气医疗集团英国有限公司 | 通过与免疫测定法偶联的核酸扩增的固体支持物上的分析物检测 |
JP2018506020A (ja) * | 2014-12-18 | 2018-03-01 | ジーイー・ヘルスケア・ユーケイ・リミテッド | 核酸増幅と組合せたイムノアッセイによる固体支持体上の被検体検出 |
US10968478B2 (en) | 2014-12-23 | 2021-04-06 | Global Life Sciences Solutions Operations UK Ltd | Methods and reagents for reverse-transcription polymerase chain reaction |
US10822645B1 (en) | 2014-12-23 | 2020-11-03 | Global Life Sciences Solutions Operations UK Ltd | Methods and reagents for reverse-transcription polymerase chain reaction |
US10858694B2 (en) | 2014-12-23 | 2020-12-08 | Global Life Sciences Solutions Operations UK Ltd | Methods and reagents for reverse-transcription polymerase chain reaction |
WO2016106129A3 (en) * | 2014-12-23 | 2016-12-08 | Ge Healthcare Uk Limited | Methods and reagents for reverse-transcription polymerase chain reaction |
WO2016106113A1 (en) * | 2014-12-23 | 2016-06-30 | Ge Healthcare Uk Limited | Methods and reagents for reverse-transcription polymerase chain reaction |
US10907148B2 (en) * | 2015-08-28 | 2021-02-02 | Global Life Sciences Solutions Operations UK Ltd | Method and kit for analyte detection |
WO2017036808A1 (en) * | 2015-08-28 | 2017-03-09 | Ge Healthcare Uk Limited | A method and kit for analyte detection |
US10590408B2 (en) | 2016-02-18 | 2020-03-17 | Ge Healthcare Uk Limited | Method and composition for biomolecule stabilization |
US11286526B2 (en) * | 2017-05-19 | 2022-03-29 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
US11952630B2 (en) * | 2017-05-19 | 2024-04-09 | Gen-Probe Incorporated | Dried compositions containing flap endonuclease |
EP4289507A3 (en) * | 2017-07-10 | 2024-02-28 | Gen-Probe Incorporated | Analytical systems and methods for nucleic acid amplification using sample assigning parameters |
CN114317700A (zh) * | 2021-12-28 | 2022-04-12 | 无锡科智达科技有限公司 | 荧光pcr试剂冻干保护剂、冻干方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104736726A (zh) | 2015-06-24 |
GB201219137D0 (en) | 2012-12-05 |
JP2018183156A (ja) | 2018-11-22 |
JP2015533507A (ja) | 2015-11-26 |
US10907201B2 (en) | 2021-02-02 |
JP7009011B2 (ja) | 2022-02-10 |
EP2912191B1 (en) | 2019-09-04 |
US20170152546A1 (en) | 2017-06-01 |
CN112899354A (zh) | 2021-06-04 |
WO2014064169A1 (en) | 2014-05-01 |
IN2015DN02793A (enrdf_load_stackoverflow) | 2015-09-04 |
EP2912191A1 (en) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10907201B2 (en) | Direct nucleic acid amplification kit, reagent and method | |
JP4585123B2 (ja) | 生体材料からのdnaの単離方法 | |
US9260711B2 (en) | Solid matrix for one step nucleic acid amplification | |
EP2917344B1 (en) | Methods for one step nucleic acid amplification of non-eluted samples | |
CA2761059C (en) | A dried and stabilized ready-to-use composition containing nucleic acid polymerization enzymes for molecular biology applications | |
AU2025204095B2 (en) | Dried compositions containing flap endonuclease | |
WO2014041093A1 (en) | Solid matrix for one step nucleic acid amplification | |
US20240318161A1 (en) | Compositions and methods for nucleic acid extraction and library preparation | |
WO2014023790A1 (en) | Polymerase chain reaction method for amplifying nucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GE HEALTHCARE UK LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HORTON, JEFFREY K.;TATNELL, PETER J.;LAMERTON, KATHRYN L.;REEL/FRAME:030124/0929 Effective date: 20130314 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |